Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Methods A retrospective observational cohort study from January 1, 2012 to September 30,
2015 was conducted using fully anonymized, pooled data from 4 large, nationally …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial
fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched …